Alpharetta, GA, July 21, 2008 --(PR.com
)-- Brookstone Pharmaceuticals, LLC today announced the introduction of Ranitidine Syrup, a generic equivalent to Zantac® Syrup (ranitidine hydrochloride).
Ranitidine, part of the Histamine-2 blockers, is used to treat and prevent ulcers in the stomach and intestines. It can also be used to treat gastro esophageal reflux disease (GERD).
Ranitidine Syrup marks the first ANDA product launch, Orange Book rated AA, and the eighth generic product in Brookstone’s rapidly growing pharmaceutical portfolio. The Alpharetta-based company launched in December, 2007 with the goal of providing affordable, high-quality, specialty generic products for the marketplace.
Ranitidine Syrup will be available for shipment beginning on July 21, 2008.
About Brookstone Pharmaceuticals, LLC
Brookstone Pharmaceuticals, LLC is committed to holding a leadership role in the field of generic pharmaceuticals, offering affordable, high-quality, specialty generic products that are no longer protected by patents. In addition Brookstone’s professional and technical teams are committed to providing ‘best in class’ customer service and support. For more information, please go online at www.brookstonepharma.com
ZANTAC is a registered trademark of Warner-Lambert Company, used under license by GlaxoSmithKline.
The foregoing release may contain forward-looking statements regarding potential additional marketing approvals or future sales of Ranitidine. Any such forward looking statement involve known and unknown risks, uncertainties and other factors that may cause actual results with Ranitidine to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Ranitidine will receive any additional marketing approvals in any other countries, or that it will reach any particular sales levels. Management’s expectation regarding Ranitidine could be affected by various risks and factors. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Brookstone Pharmaceuticals is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
Sarika Arora, Trade Relations Specialist, 678-325-5188; firstname.lastname@example.org